Retains Global Market for Detach
Retains Global Market for Detach
Brisbane, June 14, 2019 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) announces that Zoetis Inc. has given notice of termination of the exclusive worldwide license of Detach(R) for livestock and horses. Zoetis made a portfolio decision not to continue with the pursuit of this asset.

Scour (diarrhoea) in piglets is an expensive, debilitating and in some cases, life-threatening condition. Increasing survivability and providing health benefits to pre-weaning piglets has been at the core of the development of Detach(R) since the Company was listed in 2014.

In October last year, Anatara announced that the Australian Pesticides and Veterinary Medicines Authority (APVMA) had registered Detach(R) with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".

Anatara will now re-evaluate commercialisation opportunities for Detach(R) including options for launch of the APVMA approved product in Australia, regulatory approval of this product in overseas markets, development of this product for species other than piglets and, global or regional licensing of Detach(R).

Prior to executing the exclusive license agreement with Zoetis Inc., Anatara engaged with >10 top multi-national animal health companies. Anatara will now undertake a strategic review and provide an update to the market in the coming weeks.

Anatara continues to progress development of its dietary supplement for sufferers of gastrointestinal conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Eleven percent of the global population is affected by IBS(see Note 1 below), with 5 million IBD sufferers worldwide(see Note 2 below). These disorders are multicausal and no single treatment is effective for all sufferers. Over 50% of IBS(see Note 3 below) and IBD(see Note 4 below) patients try complementary and alternative medicines, in the hope of effectively managing their disorder.

Notes:

1 Clinical Gastroenterology and Hepatology 2012: 10, 712-721

2 Gastroenterology 2017: 152:415-429

3 Gastroenterology 2017: 152:415-429

4 World J. Gastroenterol 2014: 346-362


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

    


Contact

Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com



Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 18)